Impact of anti-cancer drugs and other determinants on serum protein binding of morphine 6-glucuronide

Daru

Volumn 18, Issue 2, 2010, Pages 107-113

  Mashayekhi, S O ^a   Ghandforoush Sattari, M ^b   Buss, D C ^c   Routledge, P A ^c   Hain, R D W ^d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Albumin; Morphine; Morphine 6 glucuronide; Protein binding

Indexed keywords

ANTINEOPLASTIC AGENT; BUFFER; FATTY ACID; HUMAN ALBUMIN; MERCAPTOPURINE; METHOTREXATE; MORPHINE; MORPHINE 6 GLUCURONIDE; OLEIC ACID; OROSOMUCOID; PALMITIC ACID; VINCRISTINE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD PH; BLOOD STORAGE; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; EQUILIBRIUM DIALYSIS; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MALE; METABOLITE; NEWBORN;

EID: 77954822076     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Yeh SY, Gorodetzky CW, Krebs HA. Isolation and identification of morphine 3- and 6-glucuronides, morphine 3,6-diglucuronide, morphine 3-ethereal sulfate, normorphine, and normorphine 6-glucuronide as morphine metabolites in humans. J Pharm Sci, 1977; 66(9): 1288-1293.
2. Osborne R, Thompson P, Joel S, Trew D, Patel N, Slevin M. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol, 1992; 34(2): 130-138.
3. Osborne R, Joel S, Trew D, Slevin M. Analgesic activity of morphine-6-glucuronide. Lancet 1988; 1(8589): 828.
4. Mashayekhi SO, Ghandforoush-Sattari M, Routledge PA, Hain RD. Pharmacokinetic and pharmacodynamic study of morphine and morphine 6-glucuronide after oral and intravenous administration of morphine in children with cancer. Biopharm Drug Dispos, 2009; 30(3): 99-106.
5. Vree TB, Verwey-van Wissen CP. Pharmacokinetics and metabolism of codeine in humans. Biopharm Drug Dispos, 1992; 13(6): 445-460.
6. Milne RW, Nation RL, Somogyi AA, Bochner F, Griggs WM. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br J Clin Pharmacol, 1992; 34(1): 53-59.
7. Geigy Scientific Tables. 8th ed. Basle, Switzerland: CIBA-GEIGY, 1981.
8. Mashayekhi S, Ghandforoush-sattari M, Hain R, Nixon L. Morphine-6-glucuronide assay using a competitive ELISA assay. Pharmaceutical Sciences, 2007: 51-60.
9. Mashayekhi SO, Hain RDW, Buss DC, Routledge PA. Morphine in children with cancer: impact of age, chemotherapy and other factors on protein binding. Journal of Pain & Palliative Care Pharmacotherapy, 2007; 21(3): 5-17.
10. Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol, 1998; 41(5): 347-352.
11. Kato Y, Matsushita T, Chiba K, Hijiya N, Yokoyama T, Ishizaki T. Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia. J Pediatr, 1991; 119(2): 311-316.
12. Lawrenz-Wolf B, Wolfrom C, Frickel C, Fengler R, Wehinger H, Henze G. [Severe renal impairment of methotrexate elimination after high dose therapy]. Klin Padiatr, 1994; 206(4): 319-326.
13. de Lannoy IA, Mandin RS, Silverman M. Renal secretion of vinblastine, vincristine and colchicine in vivo. J Pharmacol Exp Ther, 1994; 268(1):388-395.
14. Sjoholm I, Stjerna B. Binding of drugs to human serum albumin XVII: Irreversible binding of mercaptopurine to human serum proteins. J Pharm Sci, 1981; 70(11): 1290-1291.
15. Combe B, Edno L, Lafforgue P, Bologna C, Bernard JC, Acquaviva P, Sany J, Bressolle F. Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. Br J Rheumatol, 1995; 34(5): 421-428.
16. Wood M, Wood AJ. Changes in plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant. Clin Pharmacol Ther 1981; 29(4):522-6.
17. Lerman J, Strong HA, LeDez KM, Swartz J, Rieder MJ, Burrows FA. Effects of age on the serum concentration of alpha 1-acid glycoprotein and the binding of lidocaine in pediatric patients. Clin Pharmacol Ther, 1989; 46(2): 219-225.
18. Kodama H, Kodama Y, Itokazu N, Shinozawa S, Kanemaru R, Sugimoto T. Effect of temperature on serum protein binding characteristics of phenytoin in monotherapy paediatric patients with epilepsy. J Clin Pharm Ther, 2001; 26(3): 175-179.
19. Tiula E, Tallgren LG, Neuvonen PJ. Serum protein binding of phenytoin, diazepam and propranolol in chronic renal diseases. Int J Clin Pharmacol Ther Toxicol, 1987; 25(10): 545-552.
20. Ma Y, Henry JA. The antidotal effect of alpha(1)-acid glycoprotein on amitriptyline toxicity in cardiac myocytes. Toxicology, 2001; 169(2): 133-144.
21. Schley J, Muller-Oerlinghausen B. Investigation of the binding of various tricyclic neuroleptics and antidepressants to alpha 1-acid glycoprotein. J Pharm Pharmacol, 1986; 38(2): 102-106.
22. Fournier T, Medjoubi NN, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta, 2000; 1482(1-2):157-171.
23. Nilsen OG, Leren P, Aakesson I, Jacobsen S. Binding of quinidine in sera with different levels of triglycerides, cholesterol, and orosomucoid protein. Biochem Pharmacol, 1978; 27(6): 871-876.
24. Wilson AS, Stiller RL, Davis PJ, Fedel G, Chakravorti S, Israel BA, McGowan FX, Jr. Fentanyl and alfentanil plasma protein binding in preterm and term neonates. Anesth Analg, 1997; 84(2): 315-318.
25. Coyle DE, Denson DD, Essell SK, Santos DJ. The effect of nonesterified fatty acids and progesterone on bupivacaine protein binding. Clin Pharmacol Ther, 1986; 39(5): 559-563.
26. Spector AA, Santos EC, Ashbrook JD, Fletcher JE. Influence of free fatty acid concentration on drug binding to plasma albumin. Ann N Y Acad Sci, 1973; 226: 247-258.